The effects of oral myelin basic protein and dexamethasone treatment on experimental autoimmune encephalomyelitis.
Mokhtarian
F
F
Division of Immunology, Department of Medicine, Maimonides Medical Center, Brooklyn, New York 11219, USA.
Shirazian
T
T
Batuman
O
O
Shi
Y
Y
D000284:Administration, Oral; D000818:Animals; D000941:Antigens / Q000008:administration & dosage / Q000276:immunology; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage / Q000494:pharmacology*; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology* / Q000517:prevention & control*; D006168:Guinea Pigs; D007108:Immune Tolerance; D007274:Injections, Intraperitoneal; D008213:Lymphocyte Activation; D051379:Mice; D008815:Mice, Inbred Strains; D016685:Mitomycin / Q000494:pharmacology; D004676:Myelin Basic Protein / Q000008:administration & dosage / Q000276:immunology*; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D013154:Spleen / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
D000941:Antigens; D004676:Myelin Basic Protein; D016685:Mitomycin; D003907:Dexamethasone; D010047:Ovalbumin